Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: Quantitative assessment of inflammation and β-amyloid in the muscle

Arthritis and Rheumatism

Volumn 64, Issue 12, 2012, Pages 4094-4103

  Zschüntzsch, Jana ^a   Voss, Joachim ^b   Creus, Kim ^c   Sehmisch, Stephan ^a   Raju, Raghavan ^d   Dalakas, Marinos C ^e   Schmidt, Jens ^f,g  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF WASHINGTON   (United States)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f Gemeinnutzige Hertie Stiftung   (Germany)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ALPHA CRYSTALLIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA CRYSTALLIN; CXCL9 CHEMOKINE; DESMIN; GAMMA INTERFERON; IMMUNOGLOBULIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; PERFORIN; PREDNISONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN;

ARTICLE; CELL CULTURE; CELL DEATH; CELL STRESS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INCLUSION BODY MYOSITIS; MUSCLE BIOPSY; MUSCLE CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

AMYLOID BETA-PEPTIDES; BIOPSY; CELLS, CULTURED; CHEMOKINES; CYTOKINES; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INFLAMMATION; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; NITRIC OXIDE; PREDNISONE; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84870307394     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37692     Document Type: Article

References (40)

1. Dalakas MC,. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology 2006; 66: S33-8. (Pubitemid 43739982)
2. Needham M, Mastaglia FL,. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007; 6: 620-31. (Pubitemid 46921056)
3. Askanas V, Engel WK,. Inclusion-body myositis: a myodegenerative conformational disorder associated with Aβ, protein misfolding, and proteasome inhibition. Neurology 2006; 66: S39-48. (Pubitemid 43739983)
4. De Paepe B, Creus KK, De Bleecker JL,. Chemokines in idiopathic inflammatory myopathies. Front Biosci 2008; 13: 2548-77. (Pubitemid 351599704)
5. Raju R, Vasconcelos O, Granger R, Dalakas MC,. Expression of IFN-γ-inducible chemokines in inclusion body myositis. J Neuroimmunol 2003; 141: 125-31. (Pubitemid 37289005)
6. Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC,. Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle. Brain 2008; 131: 1228-40.
7. Wiendl H, Hohlfeld R, Kieseier BC,. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 2005; 26: 373-80. (Pubitemid 40835843)
8. Salajegheh M, Rakocevic G, Raju R, Shatunov A, Goldfarb LG, Dalakas MC,. T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology 2007; 69: 1672-9. (Pubitemid 350287123)
9. Muntzing K, Lindberg C, Moslemi AR, Oldfors A,. Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time. Scand J Immunol 2003; 58: 195-200. (Pubitemid 36904312)
10. + T cell cytotoxicity. Brain 2004; 127: 1182-90. (Pubitemid 38623051)
11. Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, et al. Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009; 132: 1536-44.
12. Badrising UA, Maat-Schieman ML, Ferrari MD, Zwinderman AH, Wessels JA, Breedveld FC, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002; 51: 369-72. (Pubitemid 34206293)
13. Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM,. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002; 58: 1081-7. (Pubitemid 34298550)
14. Quartuccio L, De Marchi G, Scott CA, Ferraccioli G, Beltrami CA, De Vita S,. Treatment of inclusion body myositis with cyclosporin-A or tacrolimus: successful long-term management in patients with earlier active disease and concomitant autoimmune features. Clin Exp Rheumatol 2007; 25: 246-51. (Pubitemid 46851428)
15. Lindberg C, Trysberg E, Tarkowski A, Oldfors A,. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003; 61: 260-2. (Pubitemid 36875317)
16. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K,. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48: 712-6. (Pubitemid 27120112)
17. Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT,. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994; 44: 1516-8. (Pubitemid 24247450)
18. Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis [published erratum appears in Neurology 2002;58:334]. Neurology 2001; 57: 1566-70.
19. Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004; 63: 718-20.
20. Dalakas MC,. Therapeutic approaches in patients with inflammatory myopathies. Semin Neurol 2003; 23: 199-206. (Pubitemid 36910120)
21. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E,. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56: 323-7. (Pubitemid 32144142)
22. Schmidt J, Barthel K, Zschuntzsch J, Muth IE, Swindle EJ, Hombach A, et al. Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β- induced accumulation of β-amyloid and cell death. Brain 2012; 135: 1102-14.
23. Raju R, Dalakas MC,. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 2005; 128: 1887-96. (Pubitemid 41373661)
24. Amemiya K, Semino-Mora C, Granger RP, Dalakas MC,. Downregulation of TGF-β1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000; 94: 99-104. (Pubitemid 30067874)
25. Dalakas MC,. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004; 291: 2367-75. (Pubitemid 38656304)
26. Gold R, Stangel M, Dalakas MC,. Drug insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 2007; 3: 36-44. (Pubitemid 46056032)
27. Quick A, Tandan R,. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. Curr Rheumatol Rep 2011; 13: 192-8.
28. Hughes RA, Dalakas MC, Cornblath DR, Latov N, Weksler ME, Relkin N,. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol 2009; 158 Suppl 1: 34-42.
29. Basta M, Dalakas MC,. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729-35. (Pubitemid 24348207)
30. Barohn RJ, Amato AA, Sahenk Z, Kissel JT, Mendell JR,. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995; 45: 1302-4.
31. 2+ release and contractility in skeletal muscle. Neurobiol Aging 2010; 31: 2080-90.
32. Muth IE, Barthel K, Bahr M, Dalakas MC, Schmidt J,. Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of αB-crystallin is associated with amyloid precursor protein and accumulation of β-amyloid. J Neurol Neurosurg Psychiatry 2009; 80: 1344-9.
33. Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005; 52: 1824-35. (Pubitemid 40852891)
34. Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, et al. Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation 2010; 7: 90.
35. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009; 30: 1728-36.
36. Brown GC, Borutaite V,. Nitric oxide inhibition of mitochondrial respiration and its role in cell death. Free Radic Biol Med 2002; 33: 1440-50. (Pubitemid 35351587)
37. Schmidt J, Dalakas MC,. Inclusion-body myositis in the elderly: an update. Aging Health 2010; 6: 687-94.
38. Pruitt JN, Showalter CJ, Engel AG,. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol 1996; 39: 139-43. (Pubitemid 26052230)
39. Li Y, Zhou W, Tong Y, He G, Song W,. Control of APP processing and Aβ generation level by BACE1 enzymatic activity and transcription. FASEB J 2006; 20: 285-92. (Pubitemid 44933176)
40. Querfurth HW, LaFerla FM,. Alzheimer's disease [published erratum appears in N Engl J Med 2011;364:588]. N Engl J Med 2010; 362: 329-44.